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Background: Fibroblast growth factor 21 (FGF21) is an emerging metabolic regulator associated with glucose and
lipid metabolism, and it is still unclear whether FGF21 is related to atherosclerosis. Here, we explored the potential
link between FGF21 and lower extremity atherosclerotic disease (LEAD) in type 2 diabetic patients.
Methods: A cross-sectional study was conducted on 504 type 2 diabetic patients (283 men, 221 women). LEAD was
defined by Ankle-brachial index (ABI) <0.9 and lower extremity arterial plaque evaluated by color Doppler ultrasound.
Serum FGF21 concentrations were quantified by a sandwich enzyme-linked immunosorbent assay.
Results: The total FGF21 levels of male and female patients had no significant differenence ((299.14(177.31-534.49) vs
362.50(214.01-578.73), P=0.516). Serum FGF21 levels in LEAD group were significantly higher than non-LEAD group in
females (385.34(243.89-661.54) vs 313.13(156.38-485.79), P=0.006), while not in male patients (295.52(177.09-549.64) vs
342.09 (198.70-549.87), P=0.613). In diabetic women, subjects with LEAD had significantly higher serum FGF21 regardless
of non-alcoholic fatty liver disease (NAFLD) (P < 0.05). And serum FGF21 levels were positively correlated with waist
circumference and systolic blood pressure after adjusted for age and BMI (r=0.198, P=0.004; r=0.152, P=0.027; respectively).
Moreover, FGF21 was independently tied to femoral intima-media thickness (FIMT) (β=0.208, P=0.031). After adjusted for
other LEAD risk factors, FGF21 was demonstrated to be an independent risk factor for LEAD in type 2 diabetic women
(OR, 1.106; 95%CI 1.008-1.223; P=0.028). In addition, FGF21 was negatively correlated with estradiol in premenopausal
diabetic women (r=−0.368, P=0.009). After adjusted for estradiol, serum FGF21 levels were still positively associated with
FIMT in premenopausal diabetic women (r=0.381, P=0.007). In diabetic men, serum FGF21 levels were correlated with
triglyceride and C-reactive protein even after adjusted for age and BMI (r=0.204, P=0.001; r=0.312, P < 0.001; respectively).
However, serum FGF21 was not an independent impact factor for LEAD in men (P > 0.05).
Conclusions: Serum FGF21 level independently and positively links LEAD in Chinese women with type 2 diabetes.
The gender difference may be due to different estrogen levels.
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Atherosclerosis is a progressive disease which affects
multiple vascular beds. And its clinical consequence in-
cluding coronary arterial disease, cerebrovascular disease
and peripheral artery disease (PAD) are potentially life-
threatening. Even the patients with higher subclinical
atherosclerosis risk have significantly higher cumulative
incidence rate of cardiovascular events [1]. In diabetic
patients, the onset of atherosclerosis was earlier [2]. Dia-
betics had significantly higher pulse wave velocity, in-
creased carotid intima-medial thickness and more
plagues than non-diabetes [3]. In fact, atherosclerotic le-
sions were more frequent in femoral arteries than ca-
rotid arteries independent of increasing number of risk
factors [4]. As one of common diabetic macrovascular
complications, lower extremity atherosclerotic disease
(LEAD) or diabetic PAD of lower extremity, was one of
the major causes of foot ulceration and amputation [5].
Early detection and treatment of LEAD is critical to pre-
vent amputation and mortality of diabetic population.
Despite the fact that LEAD is an independent predictor
of cardiovascular and cerebrovascular ischemic events,
this particular manifestation of systemic atherosclerosis
is largely under-diagnosed and undertreated [6]. There-
fore, it is vital for diabetic patients to recognize lower
limb atherosclerosis and control its risk factors as early
as possible.
Fibroblast growth factors and their receptors have a
wide range of biological functions. As we all known,
basic fibroblast growth factor (bFGF), one of FGFs iso-
mer, is involved in atherosclerosis formation [7]. But as a
member of the FGFs subfamily, fibroblast growth factor
21 (FGF21) plays an important role in regulating glucose
and lipid metabolism and insulin sensitivity in animals.
Pharmacological doses of FGF21 produce anti-diabetic,
lipid-lowering, and weight-reducing effects in rodents.
And mice with over-expression of FGF21 were protected
from diet-induced obesity [8], while FGF21 knockout
mice developed mild obesity and impaired glucose
homeostasis as these mice became aged [9]. Gaich et al.
reported the first clinical trial that FGF21 analog im-
proved the lipid profile of obese subjects with type 2 dia-
betes [10]. And FGF21 may be a promising therapeutic
target in obesity-related diseases [11]. Actually, despite
of FGF21 reduction in type 1 diabetes and latent auto-
immune diabetes in adults (LADA) [12], circulating
FGF21 levels were elevated in obesity [13], type 2 dia-
betes [14], dyslipidemia [15] and non-alcoholic fatty liver
disease (NAFLD) [16]. Shen Y et al. also showed that
FGF21 concentrations increased in coronary heart dis-
ease [17] and “FGF21 resistance”, a phenomenon rem-
iniscent of hyperinsulinemia and insulin resistance
might be one of the reasons for the increase of elevated
FGF21 [18].Except for these above findings that FGF21 was associ-
ated with metabolic dysfunction and the well-established
link between metabolic disorders and cardiovascular dis-
ease, few clinical studies have reported the potential
connection between FGF21 and atherosclerosis espe-
cially LEAD. An SY et al. found that subjects with ca-
rotid artery plaque had higher serum FGF21 levels than
those without complications [19]. A study from Ulu SM
et al. indicated that FGF21 was an independent deter-
minant of arterial stiffness in patients on dialysis [20].
Thus, the aim of the present study was to clarify the
possible link between serum FGF21 levels and LEAD in
diabetes patients.
Research design and methods
Study population
Consecutive 504 type 2 diabetic inpatients at the Shanghai
Clinical Medical Center of Diabetes from January 2013 to
December 2013 were enrolled in the study. They were
mainly local from 16 districts of Shanghai and were admit-
ted for uncontrolled hyperglycemia or diabetic complica-
tions. The diagnostic criteria of diabetes was based on the
American Diabetes Association standards [21]. Patients
with type 1 diabetes, other specific types of diabetes or
acute complications of diabetes were excluded. All the en-
rolled patients continued their previous glycemic control
regimen including hypoglycemic drugs and (or) insulin.
The study was approved by the Ethics Committee of the
Shanghai Jiao-Tong University Affiliated Sixth People’s
Hospital. The informed consents were completed by all
the participants, which were abided by the principle of the
Declaration of Helsinki.
Data collection
All subjects completed a questionnaire that collected gen-
eral background information including present and previ-
ous illness, medication, alcohol consumption and smoking
status. Hypertension was defined as systolic blood pres-
sure (SBP) ≧140 mmHg or diastolic blood pressure
(DBP) ≧90 mmHg or history of antihypertensive medi-
cine administration. Height, weight, waist circumfer-
ence (W) and blood pressure were assessed on a
standardized form by the same physician during the
health check-up. Body mass index (BMI) was calculated
as body weight (in kg) divided by the square of the height
(in m). All the patients had an overnight fast prior to the
blood samples collection.
Laboratory measurements
Blood samples were transported to the laboratory of
Shanghai Clinical Medical Center of Diabetes as needed
after collected. Fasting plasma glucose (FPG) and 2-hour
postprandial plasma glucose (2hPG) were measured by
glucose oxidase method. Glycosylated hemoglobin A1c
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matography and glycated serum albumin (GA) was mea-
sured by the liquid enzymatic assay. Serum alanine
aminotransferase (ALT) and serum lipids including total
cholesterol (TC), triglyceride (TG), highdensity lipoprotein
cholesterol (HDL-C), low density lipoprotein cholesterol
(LDL-C) were performed by enzymatic method. The glom-
erular filtration rate (GFR) was determined by technetium-
99 m diethyl triamine penta-acetic acid (Tc99m-DTPA)
clearance. Serum C-reactive protein (CRP) was measured
by particle-enhanced immunonephelometric assay (Dade
Behring Inc., Newark, NJ, USA). The serum sex hormone
including testosterone (T), estradiol (E2), progesterone (P),
luteinizing hormone (LH), follicle stimulating hormone
(FSH), prolactin (PRL), dehydroepiandrosterone sulfate
(DHEA-S) were tested by Chemoluminescence (Diasorin
company, Italy). Serum FGF21 concentration was deter-
mined by enzyme-linked immunosorbent assay (ELISA)
(Antibody and Immunoassay services, University of Hong
Kong), which give intra-batch and inter-batch variations
were 7.8% and 9.1%, respectively. Serial dilutions of recom-
binant FGF21 were included in all assays as a standard. Du-
plicate measurements were obtained for all samples.
ABI and Ultrasonography measurements
American Nieolet Versalab duplex doppler blood flow
detector was used to determine brachial and ankle arter-
ial pressure. Patients supine, with 12 cm × 40 cm gas
sleeve respectively in bilateral ankle and upper arm, with
doppler stethoscope to assist the acquisition dorsalis
pedis or tibial artery, posterior tibial artery and brachial
artery systolic blood pressure. Ankle-brachial index
(ABI) was calculated by the higher SBP in the dorsalis
pedis and posterior tibial artery devided by the higher
brachial SBP. The lower value of ABI in either limb was
used for analysis. The arterial lesion of lower extremity
artery were evaluated by color Doppler ultrasound
examination, and the femoral intima-media thickness
(FIMT) were also recorded. Color duplex ultrasonog-
raphy was conducted by three trained, certified sonogra-
phers using a Acuson Sequoia 512 scanner (Siemens
Medical Solutions, Mountain View, CA) with a 5–
13 MHz linear transducer according to our previous
method [22]. The study procedure involved scanning bi-
lateral common femoral artery, profunda femoris artery,
superficial femoral artery, popliteal artery, anterior tibial
artery, posterior tibial artery, and peroneal artery for the
presence of atherosclerotic plaque and stenosis. The
FIMT on both sides was measured as the distance be-
tween the leading edge of the lumen-intima echo and
the leading edge of the media-adventitia echo. Mean
FIMT was defined as the mean values of bilateral FIMTs.
Lower limb atherosclerotic plaque was defined as the
presence of a focal structure encroaching into thearterial lumen of 0.5 mm or at least 50% greater than
the thickness of the surrounding vessel wall or IMT of
>1.5 mm in any of the above-mentioned lower limb ar-
teries segments based on the Mannheim consensus [23].
LEAD was defined by ABI < 0.9 and lower extremity ar-
terial plaque existed. Those with an ABI > 1.3 were ex-
cluded from the analysis to avoid those with significant
medical artery layer calcification, which is independent of
atherosclerotic plagues. Others individuals were named as
non-LEAD.
Diagnostic criteria for non-alcoholic fatty liver disease
(NALFD)
NALFD was diagnosed by B ultrasonography. Hepatic
steatosis was defined by a diffuse increase of fine
echoes in the liver parenchyma compared with that in
the kidney or spleen parenchyma according to the
2010 Prevention and Treatment Guidelines for NALFD
published by the society of Hepatology, Chinese Med-
ical Association [24].
Data analysis
All the statistical analysis was performed by SPSS 21.0
(SPSS Inc., Chicago, IL). The one-sample Kolmogorov-
Smirnov test was performed to determine normality of
the data distribution. Normally distributed data were
expressed as mean ± standard deviation (SD), and data
with skewed distribution were expressed as median with
interquartile range. Differences between groups were
evaluated with Student’s t test or Mann–Whitney U test.
Categorical variables were presented as frequency per-
centage, and intergroup comparisons were analyzed
using a Chi-square test. The association between FGF21
and other variables were evaluated with Spearman cor-
relation and partial correlation analysis. Logistic regres-
sion analysis was performed to evaluate the odds ratio of
LEAD. Multiple stepwise regression analysis was used to
explore the influence of different variables on FIMT. To
determine the independent predictors for the presence
of LEAD, all the conventional risk factors related with
LEAD as well as the disease-related therapies were
tested in multivariable logistic regression. The threshold
of statistical significance was set at 0.05 for two-tailed
P-values.
Results
The mean age of the 504 study subjects was 58 years, the
media diabetes duration was 9 years, and the median level
of serum FGF21 was 327.03 ng/mL, with an interquartile
range of 190.05–545.55 ng/mL. Comparison of the preva-
lence of LEAD stratified by sex and age was shown in
Figure 1. The prevalence of LEAD significantly increased
with age both in diabetic men and women (P < 0.05).
FGF21 levels were not significantly different between male
Figure 1 Comparison of prevalence of LEAD stratified by age
and sex in type 2 diabetic patients. White bars: men; black bars:
women. Trend analysis, p < 0.001.
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(214.01-578.73), P = 0.516).
The clinical characteristics of LEAD and non-LEAD pa-
tients with respect to sex are shown in Table 1. In female
subgroup, there were significant differences in age, dia-
betes duration, SBP, prevalence of hypertension and anti-
hypertensive therapy between LEAD and non-LEAD
patients (P < 0.05). In male subgroup, there were signifi-
cant differences in age, diabetes duration, prevalence of
hypertension and anti-hypertensive therapy, FPG, TC, TG,
LDL-C, HbA1c and GA between LEAD and non-LEAD
patients (P < 0.05). FIMT values were significantly higher
in LEAD than in non-LEAD group in both male patients
and female patients (P < 0.05). Serum levels of FGF21 in
LEAD group were significantly higher than non-LEAD
group in female patients (385.34(243.89-661.54) vs.
313.13(156.38-485.79), P = 0.006), while not in male pa-
tients (295.52(177.09-549.64) vs. 342.09(198.70-549.87),
P = 0.613) (Figure 2). As is shown in Figure 3, both sub-
jects with and without NAFLD showed a significant ele-
vation of serum FGF21 levels in the LEAD group
compared to the non-LEAD group (P < 0.05).
In order to find out the influencing factors for FGF21,
Spearman correlation analysis of clinical and biochem-
ical parameters with FGF21 were undertaken. In female
patients, FGF21 was positively correlated with age, BMI,
W, SBP, DBP, TG, FCP and 2hCP, but was negatively as-
sociated with HDL-C (P < 0.05). Serum FGF21 level was
not correlated with CRP in female patients (P > 0.05).
Even after adjusted for age and BMI, FGF21 was still
positively associated with W and SBP (r = 0.198, P =
0.004; r = 0.152, P = 0.027; respectively). In male group,
serum FGF21 level was correlated with TG and CRP
(P < 0.05) (Table 2). After adjusted for age and BMI,
FGF21 level was still correlated with TG and CRP
(r = 0.204, P = 0.001; r = 0.312, P < 0.001; respectively).
Since there was gender difference of association between
FGF21 and LEAD, women were further divided into two
subgroups and compared according whether menopauseor not. There was no significant difference in FGF21 levels
between menopausal and pre-menopausal women [360.51
(228.16-529.75) vs 363.54(208.57-593.95), P > 0.05]. It
showed that FGF21 was negatively correlated with E2 in
premenopausal diabetic women (r = −0.368, P = 0.009)
(Table 3). After adjusted for estradiol, serum FGF21 level
was still positively associated with FIMT in premeno-
pausal diabetic women (r = 0.381, P = 0.007).
In order to determine which factors were independently
associated with LEAD, logistic regression was performed.
Independent variables were set as metabolic risk factors
(including age, diabetes duration, smoking status, presence
of hypertension,ALT, GFR, HbA1c, waist circumference,
dyslipidemia, anti-diabetic therapy, anti-hypertensives,
lipid-lowering therapy and serum FGF21 levels). In female
patients, logistic regression analysis of LEAD showed that
age (OR, 1.235; 95%CI (1.133-1.347); P < 0.001), hyperten-
sion (OR, 3.231; 95%CI 1.102-9.470; P = 0.033), FGF21
(OR, 1.106; 95%CI 1.008-1.223; P = 0.028) were independ-
ent impact factors for LEAD. In male patients, only age
(OR, 1.171; 95%CI (1.097-1.249); P < 0.001) was inde-
pendent associated factor for LEAD (Table 4). After ad-
justment for the confounding variables described
above, multiple stepwise regression analysis showed
that the age (β = 0.519, P < 0.001), FGF21 (β = 0.208, P =
0.031), HbA1c (β = 0.225, P = 0.020) were independent
risk factors for FIMT in type 2 diabetes women. While
in male patients, only age (β = 0.539, P < 0.001) was in-
dependently associated with FIMT (Table 5).
Discussions
In this study we provide the evidence for the first time
that elevated serum FGF21 levels are associated with
LEAD in female type 2 diabetic patients independent of
established risk factors.
Our research group had shown that increased level of
serum FGF21 was associated with NAFLD and mRNA
expression of FGF21 has been shown to increase in
hepatic biopsies [16]. Furthermore, a 3 year follow-up
of NALFD subject outcome indicated that serum
FGF21 level might be a clinically-relevant disease bio-
marker for NALFD [25]. In the current study, a signifi-
cant elevation of serum FGF21 among LEAD subjects
was found independently of NALFD status. Multivari-
able logistic regression analysis also identified serum
FGF21 level as one of the independent risk factors for
LEAD.
The mechanism linking FGF21 with atherosclerosis was
currently not well understood. Elevated mRNA expression
of FGF21 was found in rat cardiac micro-vascular endo-
thelial cells (CMECs) cultured in atherosclerosis-like con-
ditions [26]. Furthermore, exogenous FGF21 infusion to
the CMECs atherosclerosis promoting culture significantly
inhibited the apoptosis of cells. These findings suggested
Table 1 Clinical and biochemical characteristics of participants
Variables Men P Women P
LEAD Non-LEAD LEAD Non-LEAD
Age(year) 61.75 ± 10.31 47.55 ± 10.07 <0.001 64.40 ± 9.79 56.62 ± 9.52 <0.001
Diabetes duration(year) 10(5–15) 3(0.48-10) <0.001 13.14 ± 7.73 7.85 ± 5.64 <0.001
Body mass index(kg/cm2) 23.59 ± 3.53 25.99 ± 3.20 0.194 25.12 ± 3.83 25.37 ± 3.89 0.655
Waist circumference(cm) 93.23 ± 10.89 94.80 ± 10.17 0.273 91.19 ± 11.35 88.02 ± 10.49 0.055
Systolic blood pressure(mmHg) 130(120–140) 130(120–140) 0.503 135(123.5-150) 129(120–135) <0.001
Diastolic blood pressure(mmHg) 80(70–85) 80(78–90) 0.010 80(75–85) 80(70–85) 0.268
Fasting plasma glucose(mmol/L) 6.88(5.92-9.07) 7.92(6.50-10.36) 0.007 8.03 ± 2.62 2.97 ± 0.91 0.409
2 h postprandial plasma glucose(mmol/L) 12.96 ± 4.40 13.73 ± 4.53 0.212 14.31 ± 4.57 13.48 ± 4.61 0.232
Fasting C-peptide(ng/ml) 1.93 ± 1.03 2.12 ± 1.13 0.213 1.95 ± 1.07 2.07 ± 1.15 0.472
2-h postprandial C peptide(ng/ml) 4.98 ± 3.18 5.07 ± 3.50 0.854 4.90 ± 3.26 5.11 ± 2.99 0.664
Total cholesterol(mmol/L) 4.46 ± 1.11 4.98 ± 1.17 0.001 4.92 ± 1.10 5.08 ± 1.16 0.352
Triglyceride(mmol/L) 1.92(1.16-3.63) 1.40(0.93-2.10) 0.005 1.42(1.05-1.93) 1.46(0.98-2) 0.720
High-density lipoprotein cholesterol(mmol/L) 1.00 ± 0.24 0.97 ± 0.21 0.397 1.15 ± 0.32 1.18 ± 0.33 0.481
Low-density lipoprotein cholesterol(mmol/L) 2.63 ± 0.89 2.96 ± 0.80 0.006 2.86 ± 0.97 2.97 ± 0.91 0.409
Glycated hemoglobin A1c(%) 8.0(7.1-9.85) 9.1(7.45-10.85) 0.023 8.82 ± 1.86 8.62 ± 1.85 0.459
Glycated serum albumin(%) 22.30 ± 7.18 24.44 ± 8.07 0.044 20.9(17.75-26.30) 20.10(17.20-25.3) 0.364
Alanine aminotransferase(U/L) 21(14–27) 24(18–36.5) 0.065 18(13–31.75) 22(14.75-30) 0.303
Aspartate aminotransferase(U/L) 19(16–23) 19(15–28) 0.423 19(16–24) 20(15–25.5) 0.894
γ-glutamyl transpeptidase(U/L) 27(19–39) 31(21–42.5) 0.065 23(16.75-39) 28(18.50-44) 0.160
Glomerular filtration rate(ml/min/1.73 m2) 97.04 ± 24.04 96.34 ± 24.92 0.845 94.67 ± 25.79 98.37 ± 23.23 0.355
C reactive protein(mg/L) 1.67(0.64-2.57) 1.10(0.56-2.35) 0.347 1.3(0.53-2.65) 1.45(0.75-3.11) 0.256
Femoral intima-media thickness(mm) 0.85 ± 0.06 0.67 ± 0.12 <0.001 0.86 ± 0.03 0.70 ± 0.11 <0.001
Smoking(%) 55.8 54.9 0.888 0.8 2.7 0.278
Drinking(%) 24.5 19.5 0.233 1.6 1.4 0.903
Hypertension(%) 60.7 36.6 <0.001 62.7 37.0 <0.001
Anti-hypertensive therapy(%) 47.1 18.9 <0.001 48.6 20.3 <0.001
Anti-diabetic therapy(%) 78.9 77.1 0.732 68.9 66.4 0.453
Lipid-lowing therapy(%) 15.8 14.3 0.677 12.8 10.3 0.566
Estradiol 115.24 ± 58.72 116.54 ± 56.01 0.889 70.94(38.73-104.91) 88.95(50.10-165.27) 0.039
Testosterone 12.61 ± 5.25 12.64 ± 4.56 0.972 1.18(0.89-1.55) 1.26(0.94-1.69) 0.610
Progestogen 1.04(0.75-1.47) 1.03(0.71-1.33) 0.516 0.82(0.65-1.42) 0.80(0.64-1.90) 0.756
Follicle-Stimulating Hormone 9.43(6.40-14.41) 6.50(4.00-9.04) <0.001 52.53 ± 23.61 38.08 ± 25.33 0.001
Luteinizing hormone 5.92(3.98-9.56) 4.96(3.24-6.48) 0.002 23.78 ± 10.53 20.16 ± 13.69 0.960
Prolactin 168.83(136.86-214.16) 171.39(109.74-242.44) 0.002 193.70 ± 85.48 185.66 ± 138.83 0.707
Dehydroepiandrosterone sulfate 201.13 ± 106.74 260.10 ± 117.77 0.001 126.50 ± 66.74 173.73 ± 81.99 <0.001
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the early stage of atherosclerosis, helping the cells to re-
cover normal endothelial function. FGF21 also has anti-
oxidant effects in atherosclerotic rat, such that increased
levels of superoxide dismutase, reduced glutathione, and
reduced malondialdehyde [27]. Another study found the
protective effect of FGF21 on atherosclerosis might be in
part due to its inhibition on endoplasmic reticulum stress-
mediated apoptosis [28].Actually in human study, circulating FGF21 levels are
elevated in obesity, type 2 diabetes and dyslipidemia. It
was proposed that the elevated level of FGF21 was at-
tributed to FGF21 resistance, a phenomenon reminiscent
of hyperinsulinemia and insulin resistance. One of the
reasons of elevated FGF21 could be the presence of
compensatory response to higher metabolic stress. A re-
cent study suggested that adipose tissue inflammation in
obesity could lead to the repression of beta-Klotho
Figure 2 Comparison of serum FGF21 levels in LEAD and
non-LEAD subgroup stratified by sex. White bars: men; Grey
bars: women.
Table 2 Correlation of FGF21 with anthropometric and
biochemical variables
Covariables Women Men
r P r P
Age(year) 0.031 0.647 −0.011 0.858
Diabetes duration(year) −0.030 0.662 −0.015 0.805
Body mass index(kg/cm2) 0.160 0.018 0.081 0.179
Waist circumference(cm) 0.188 0.005 0.074 0.218
Systolic blood pressure(mmHg) 0.200 0.003 −0.036 0.551
Diastolic blood pressure(mmHg) 0.176 0.009 −0.036 0.557
Fasting plasma glucose(mmol/L) 0.005 0.945 −0.003 0.958
2 h postprandial plasma
glucose(mmol/L)
0.073 0.290 −0.092 0.139
Fasting C-peptide(ng/ml) 0.168 0.017 0.102 0.106
2-h postprandial C peptide(ng/ml) 0.149 0.034 0.014 0.845
Total cholesterol(mmol/L) 0.036 0.606 0.088 0.160
Triglyceride(mmol/L) 0.245 <0.001 0.21 0.001
High-density lipoprotein
cholesterol(mmol/L)
−0.192 0.006 −0.091 0.147
Low-density lipoprotein
cholesterol(mmol/L)
−0.044 0.524 −0.007 0.906
Glycated hemoglobin A1c(%) 0.047 0.493 0.057 0.366
Glycated serum albumin(%) −0.001 0.985 −0.011 0.865
C reactive protein(mg/L) 0.150 0.032 0.222 <0.001
Femoral intima-media thickness(mm) 0.151 0.048 0.022 0.709
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cytes [29]. Hence we can infer it is very likely that simi-
lar actions lead to the FGF21 resistance in subclinical
inflammation such as LEAD. Thus, it is possible that
the elevated FGF21 observed in the LEAD subjects of
our study represent a similar compensatory mechanism,
by which the system is attempting to protect against
atherosclerosis.
In our study, we observed the gender-specific associ-
ation between serum FGF21 and LEAD. Chow WS et al.
also found this association was gender-specific, they
found that serum FGF21 levels positively correlated with
carotid IMT in women (r = 0.32; P < 0.001) but not in
men (r = 0.06; P = 0.305) [30]. As we all know, E2 pro-
tected premenopausal women from cardiovascular dis-
ease. While in postmenopausal women, the prevalence
of macrovascular diseases was higher. Based on these
observations, the relationship between FGF21 and hor-
monal parameters were assessed in our study. In our
data, it was found that FGF21 was negatively correlated
with E2 in diabetic women. In polycystic ovary syn-
drome and healthy subjects, a positive correlation wasFigure 3 Serum FGF21 levels among subjects with NAFLD
and/or LEAD (data from women only). White bars: non-LEAD;
Grey bars: LEAD.also found between FGF21 and LH and T (r = 0.43
p = 0.007; r = 0.38, P = 0.02, respectively) [31]. Another
study found there was a significantly negative correl-
ation between FGF21 and dehydroepiandrosterone sulfte
(DHEAS) (r = −0.309 p = 0.003) [32]. This significant cor-
relation between FGF21 and sex hormone in our study
group arises a need of new studies to explain the potential
role of FGF21 in atherosclerosis pathogenesis. Our finding
of the gender-specific association between serum FGF21
and LEAD remains to be confirmed in further studies.
In our study, FGF21 was found to positively corre-
lated to BMI, W, TG, but negatively link with HDL-C
in diabetic patients. Some of these relationships have
been described in the previous studies [13,33,34]. But
there are only limited information about the relation-
ships of FGF21 and hypertension in literature. In our
study, positive associations of FGF21 and SBP were
found in diabetic patients. The same result was found
in Japanese subjects [35]. CRP reflecting systemic in-
flammation, was a well-established marker of athero-
sclerosis and one of the classical biomarkers for
increasing risk of PAD [36]. And CRP might play a role
in the progression of PAD in diabetic patients [37]. A
recent study of 69 newly diagnosed diabetes subjects
demonstrated a positive correlation between serum FGF21
Table 3 Correlation of FGF21 with sex hormone by Spearman analysis
Covariables Postmenopausal (n = 143) Premenopausal (n = 78) Men (n = 283)
r P r P r P
Estradiol 0.07 0.593 −0.368 0.009 0.092 0.212
Testosterone 0.029 0.795 0.149 0.288 −0.09 0.213
Progestogen −0.221 0.201 −0.148 0.383 0.045 0.602
Follicle-Stimulating Hormone −0.029 −0.798 0.009 0.949 −0.093 0.2
Luteinizing hormone 0.034 0.762 −0.104 0.456 0.003 0.966
Prolactin −0.033 0.769 −0.147 0.288 0.113 0.122
Dehydroepiandrosterone sulfate −0.076 0.493 0.212 0.123 −0.018 0.805
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linked with CRP in the present study (r = 0.15 P = 0.032).
Consistent with other studies, we found that some of the
traditional risk factors for atherosclerosis were also present
in this population. As expected, age, hypertension were in-
dependently associated with the presence of LEAD in the
type 2 diabetes women. Therefore, strict control of hyper-
tension is important in order to prevent atherosclerosis in
the lower limb arteries in diabetic patients.
The strength of this study is that GFR was directly
measured by the 99mTc-DTPA renal dynamic imaging ra-
ther than estimated from serum creatinine, which was
more accurate and avoided the impact from serum cre-
atinine. Several previous studies reported a close associ-
ation between chronic renal insufficiency and PAD [39].
Our previous study also revealed that the degree of per-
ipheral arterial lesion was significantly correlated with
renal function and GFR. In our study, the difference of
GFR between LEAD and Non-LEAD women patients
was not significant, the increased serum FGF21 did not
result in the dysfunction of kidney.
Lenart-Lipińska M et al. showed that serum FGF21 is
predictive of combined cardiovascular morbidity and mor-
tality in patients with type 2 diabetes at 24 months follow-
up [40]. Another larger scale study showed higher baseline
plasma FGF21 levels were associated with higher risk of
cardiovascular events in patients with type 2 diabetes overTable 4 Independent factors for LEAD in men and women
by multivariable logistic regression analysis
β S.E Wald OR(95% CI) P
Female
Age 0.211 0.044 22.868 1.235(1.133-1.347) <0.001
Hypertension 1.173 0.549 4.570 3.231(1.102-9.470) 0.033
FGF21 0.113 0.036 3.537 1.106(1.008-1.223) 0.028
Male
Age 0.157 0.033 22.719 1.171(1.097-1.249) <0.001
Notation: S.E., standard error; OR, odds ratio; CI, confidence interval. Variables
included in the model were age, diabetes duration, smoking status, presence
of hypertension, ALT, GFR, HbA1c, W, dyslipidemia, anti-diabetic therapy,
anti-hypertensives, lipid-lowering therapy and serum FGF21 levels.5 years follow-up in 9,697 individuals with type 2 diabetes
participating in the Fenofibrate Intervention and Event
Lowering in Diabetes (FIELD) study [41]. A follow-up of
the outcome in LEAD subjects is necessary to elucidate
whether serum FGF21 level might be a clinically-relevant
vascular disease biomarker.
Limitations
There were some limitations of our study. Firstly, the
cross-sectional design restricted our ability to assess the
evolutionary process of atherosclerotic lesions. Secondly,
this was merely a single-center study with a relatively
small number of patients. Thirdly, some other confound-
ing affecting factors of LEAD were not excluded. Further
in vivo and in vitro studies are needed to elucidate the
essential relationship between FGF21 and LEAD and the
underlying detailed mechanism in diabetes.
Conclusion
In conclusion, serum FGF21 levels independently and
positively connect with LEAD in Chinese women with
type 2 diabetes after adjusted for the traditional risk fac-
tors, and its gender difference may be due to the differ-
ence of estrogen levels. Further studies revealing the
immanent connection of FGF21 with the pathology of
diabetic peripheral vascular disorders may provide a new
prospective strategy for LEAD.Table 5 Multiple stepwise linear regression analysis of FIMT
Standardized β t P
Female
Age 0.519 5.495 <0.001
FGF21 0.208 2.202 0.031
HbA1c 0.225 2.387 0.020
Male
Age 0.539 0.254 <0.001
Notation: Variables included in the model were age, diabetes duration,
smoking status, presence of hypertension, ALT, GFR, HbA1c, W, dyslipidemia,
anti-diabetic therapy, anti-hypertensives, lipid-lowering therapy and serum
FGF21 levels.
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